Literature DB >> 26341922

Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.

Irena Misiewicz-Krzeminska1, María E Sarasquete2, Carolina Vicente-Dueñas3, Patryk Krzeminski2, Katarzyna Wiktorska4, Luis Antonio Corchete2, Dalia Quwaider2, Elizabeta A Rojas2, Rocío Corral5, Ana A Martín6, Fernando Escalante7, Abelardo Bárez8, Juan Luis García2, Isidro Sánchez-García3, Ramón García-Sanz9, Jesús F San Miguel10, Norma C Gutiérrez11.   

Abstract

PURPOSE: Dysregulation of one of the three D-cyclin genes has been observed in virtually all multiple myeloma tumors. The mechanisms by which CCND2 is upregulated in a set of multiple myeloma are not completely deciphered. We investigated the role of post-transcriptional regulation through the interaction between miRNAs and their binding sites at 3'UTR in CCND2 overexpression in multiple myeloma. EXPERIMENTAL
DESIGN: Eleven myeloma cell lines and 45 primary myeloma samples were included in the study. Interactions between miRNAs deregulated in multiple myeloma and mRNA targets were analyzed by 3'UTR-luciferase plasmid assay. The presence of CCND2 mRNA isoforms different in length was explored using qRT-PCR, Northern blot, mRNA FISH, and 3' rapid amplification of cDNA ends (RACE)-PCR.
RESULTS: We detected the presence of short CCND2 mRNA, both in the multiple myeloma cell lines and primary cells. The results obtained by 3'RACE experiments revealed that changes in CCND2 3'UTR length are explained by alternative polyadenylation. The luciferase assays using plasmids harboring the truncated CCND2 mRNA strongly confirmed the loss of miRNA sites in the shorter CCND2 mRNA isoform. Those multiple myelomas with greater abundance of the shorter 3'UTR isoform were associated with significant higher level of total CCND2 mRNA expression. Furthermore, functional analysis showed significant CCND2 mRNA shortening after CCND1 silencing and an increased relative expression of longer isoform after CCND1 and CCND3 overexpression, suggesting that cyclin D1 and D3 could regulate CCND2 levels through modifications in polyadenylation-cleavage reaction.
CONCLUSIONS: Overall, these results highlight the impact of CCND2 3'UTR shortening on miRNA-dependent regulation of CCND2 in multiple myeloma. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26341922     DOI: 10.1158/1078-0432.CCR-14-2796

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  Future of Personalized Therapy Targeting Aberrant Signaling Pathways in Multiple Myeloma.

Authors:  Faiz Anwer; Kevin Mathew Gee; Ahmad Iftikhar; Mirza Baig; Atlantis Dawn Russ; Sabina Saeed; Muhammad Abu Zar; Faryal Razzaq; Jennifer Carew; Steffan Nawrocki; Hussam Al-Kateb; Nadia Nunes Cavalcante Parr; Ali McBride; Jason Valent; Christy Samaras
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-03-25

Review 2.  Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.

Authors:  Michael Heider; Katharina Nickel; Marion Högner; Florian Bassermann
Journal:  Oncol Res Treat       Date:  2021-11-08       Impact factor: 2.825

3.  miR-1297 inhibits osteosarcoma cell proliferation and growth by targeting CCND2.

Authors:  Pan Jiang; Lianghao Mao; Xuan Lei; Chunshan Luo; Yiming Zhang; Xinyu Zhong; Zhenyu Yin; Xiaofeng Xu; Dapeng Li; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 4.  Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk.

Authors:  Patrick Hagen; Mark Sellin; Stephanie Berg; Jiwang Zhang
Journal:  Ann Hematol       Date:  2022-05-18       Impact factor: 4.030

5.  Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia.

Authors:  Hidemasa Matsuo; Kenichi Yoshida; Kazutaka Fukumura; Kana Nakatani; Yuki Noguchi; Saho Takasaki; Mina Noura; Yusuke Shiozawa; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Ai Okada; Yasuhito Nannya; June Takeda; Hiroo Ueno; Norio Shiba; Genki Yamato; Hiroshi Handa; Yuichiro Ono; Nobuhiro Hiramoto; Takayuki Ishikawa; Kensuke Usuki; Ken Ishiyama; Shuichi Miyawaki; Hidehiro Itonaga; Yasushi Miyazaki; Machiko Kawamura; Hiroki Yamaguchi; Nobutaka Kiyokawa; Daisuke Tomizawa; Takashi Taga; Akio Tawa; Yasuhide Hayashi; Hiroyuki Mano; Satoru Miyano; Yasuhiko Kamikubo; Seishi Ogawa; Souichi Adachi
Journal:  Blood Adv       Date:  2018-11-13

Review 6.  The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.

Authors:  Nikolaos Giannakoulas; Ioannis Ntanasis-Stathopoulos; Evangelos Terpos
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

7.  ETV transcriptional upregulation is more reliable than RNA sequencing algorithms and FISH in diagnosing round cell sarcomas with CIC gene rearrangements.

Authors:  Yu-Chien Kao; Yun-Shao Sung; Chun-Liang Chen; Lei Zhang; Brendan C Dickson; David Swanson; Sumathi Vaiyapuri; Farida Latif; Abdullah Alholle; Shih-Chiang Huang; Jason L Hornick; Cristina R Antonescu
Journal:  Genes Chromosomes Cancer       Date:  2017-03-31       Impact factor: 4.263

Review 8.  The pivotal role of DNA methylation in the radio-sensitivity of tumor radiotherapy.

Authors:  Xueru Zhu; Yiting Wang; Li Tan; Xiaolong Fu
Journal:  Cancer Med       Date:  2018-06-27       Impact factor: 4.452

9.  Transcriptomics Analysis of the Tumor-Inhibitory Pathways of 6-Thioguanine in MCF-7 Cells via Silencing DNMT1 Activity.

Authors:  Hao Li; Xinglan An; Daoyu Zhang; Qi Li; Nan Zhang; Hao Yu; Ziyi Li
Journal:  Onco Targets Ther       Date:  2020-02-11       Impact factor: 4.147

10.  A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Authors:  Irena Misiewicz-Krzeminska; Luis Antonio Corchete; Elizabeta A Rojas; Joaquín Martínez-López; Ramón García-Sanz; Albert Oriol; Joan Bladé; Juan-José Lahuerta; Jesús San Miguel; María-Victoria Mateos; Norma C Gutiérrez
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.